Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, a programmed death receptor-1 (PD-1) blocking antibody; AGEN1181, a human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody that is in Phase 2 trials in metastatic colorectal cancer (mCRC), pancreatic cancer, and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in clinical development; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monoclonal antibodies; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract t; and AGEN1884. The company operates under the Agenus, MiNK, Prophage, Retrocyte Display, and STIMULON trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., UroGen Pharma Ltd., Gilead Sciences, Inc., Incyte Corporation, and Merck Sharp & Dohme. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Agenus Inc.

Agenus Inc. ($AGEN) announced an update on their ongoing clinical study. The Phase II study “A Randomized, Open-Label, Phase II Trial of Nab-paclit...

Agenus Nears Key Readout as Botensilimab Pancreatic Cancer Trial Reaches Completion

FTSE Russell has released its preliminary changes for the Russell 3000 Index ahead of the official rebalancing on June 26, putting several healthca...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	AGEN	$3.00	+1.35%	868.40K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	AGEN	$3.00	+1.4%	868.40K
3
4
5
6

AGEN

AGEN

Recent News for AGEN

Get Agenus Inc. Data in Excel

Get Agenus Inc. Data in Excel